CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Panbela Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Panbela Therapeutics Inc
712 Vista Blvd # 305
Phone: (952) 479-1196p:952 479-1196 WACONIA, MN  55387  United States Ticker: PBLAPBLA
Business Summary
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Michael T.Cullen 78 5/25/2021 9/4/2015
President, Chief Executive Officer, Director Jennifer K.Simpson 52 7/15/2020 7/15/2020
Lead Independent Vice Chairman of the Board Jeffrey S.Mathiesen 62 3/19/2019 9/24/2015
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cancer Prevention Pharmaceuticals Inc 1760 E River Rd Ste 250 TUCSON AZ United States

Business Names
Business Name
Cancer Prevention Pharma (Ireland) Limited
Cancer Prevention Pharma Limited
Cancer Prevention Pharmaceuticals Inc
8 additional Business Names available in full report.

General Information
Number of Employees: 7 (As of 3/22/2024)
Outstanding Shares: 4,854,831 (As of 11/11/2024)
Shareholders: 55
Stock Exchange: OTC
Federal Tax Id: 870543922


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024